STATINS SLOW PROSTATE GROWTH: RESULTS FROM THE REDUCTION BY DUTASTERIDE OF CANCER EVENTS (REDUCE) TRIAL

被引：0

作者：

Muller, Roberto

Gerber, Leah

Moreira, Daniel

Andriole, Gerald

Parsons, J. Kellogg

Fleshner, Neil

Freedland, Stephen

机构：

来源：

JOURNAL OF UROLOGY | 2012年 / 187卷 / 04期

关键词：

D O I：

10.1016/j.juro.2012.02.1567

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

1249

引用

页码：E505 / E505

页数：1

共 50 条

[31] EVALUATION OF SAFETY AND ABILITY OF DUTASTERIDE TO IMPROVE URINARY PARAMETERS IN SUBJECTS WITH LOW TESTOSTERONE IN THE REDUCTION BY DUTASTERIDE IN PROSTATE CANCER EVENTS (REDUCE) STUDY
Marberger, Michael
Freedland, Stephen
Rittmaster, Roger
Wilson, Timothy
Castro, Ramiro
[J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E564 - E565
[32] The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study.
Bostwick, D. G.
Tindall, D. J.
Pettaway, C. A.
Tammela, T. L.
Teloken, C.
Wilson, T. H.
Castro, R. S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[33] LOGISTIC REGRESSION MODELING OF FACTORS AFFECTING RATES OF HIGH GRADE PROSTATE CANCER IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) STUDY
Andriole, Gerald L.
Tindall, Donald J.
Tamella, Tuevo L. J.
Somerville, Matthew C.
Rittmaster, Roger S.
[J]. JOURNAL OF UROLOGY, 2011, 185 (04): : E518 - E519
[34] INFLUENCE OF BASELINE PATIENT CHARACTERISTICS ON THE INCIDENCE OF HIGH-GRADE (GLEASON SCORE ≥7) BIOPSY-DETECTABLE PROSTATE CANCER EVENTS IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL
Gomella, Leonard G.
Tindall, Donald J.
Rittmaster, Roger S.
Wilson, Timothy H.
[J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 800 - 801
[35] Worldwide comparison of prostate needle biopsy quality in the reduction by dutasteride of prostate cancer events (REDUCE) study: Improvement with investigator training
Bostwick, D. G.
Teloken, C.
Brawley, O. W.
Marberger, M.
Qian, J.
Drewnowska, K.
Niyuhire, F.
Rittmaster, R. R.
Fowler, I. L.
Somerville, M. C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[36] Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial
Kattan M.W.
Earnshaw S.R.
McDade C.L.
Black L.K.
Andriole G.L.
[J]. Applied Health Economics and Health Policy, 2011, 9 (5) : 305 - 315
[37] Comparison of Classic and International Society of Urological Pathology 2005 Modified Gleason Grading Using Needle Biopsies From the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial
Lucia, M. Scott
Bostwick, David G.
Somerville, Matthew C.
Fowler, Ivy L.
Rittmaster, Roger S.
[J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2013, 137 (12) : 1740 - 1746
[38] Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study
Feng, Tom
Howard, Lauren E.
Vidal, Adriana C.
Moreira, Daniel M.
Castro-Santamaria, Ramiro
Andriole, Gerald L.
Freedland, Stephen J.
[J]. INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (02) : 151 - 156
[39] Statins May Slow Prostate Growth
Printz, Carrie
[J]. CANCER, 2012, 118 (18) : 4369 - 4369
[40] Re: Serum Cholesterol and Risk of Lower Urinary Tract Symptoms Progression: Results from the Reduction by Dutasteride of Prostate Cancer Events Study
Kaplan, Steven A.
[J]. JOURNAL OF UROLOGY, 2019, 202 (04): : 635 - 635

← 1 2 3 4 5 →